AR090582A1 - METODOS Y COMPOSICIONES PARA TRATAR CANCER USANDO ARNhc SRC 3 BIFUNCIONAL - Google Patents

METODOS Y COMPOSICIONES PARA TRATAR CANCER USANDO ARNhc SRC 3 BIFUNCIONAL

Info

Publication number
AR090582A1
AR090582A1 ARP130101077A ARP130101077A AR090582A1 AR 090582 A1 AR090582 A1 AR 090582A1 AR P130101077 A ARP130101077 A AR P130101077A AR P130101077 A ARP130101077 A AR P130101077A AR 090582 A1 AR090582 A1 AR 090582A1
Authority
AR
Argentina
Prior art keywords
src
compositions
methods
bifunctional
rna
Prior art date
Application number
ARP130101077A
Other languages
English (en)
Inventor
Lonard David
Senzer Neil
W Omalley Bert
J Nemunaitis John
Rao Donald
Wang Zhaohui
Original Assignee
Gradalis Inc
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gradalis Inc, Baylor College Medicine filed Critical Gradalis Inc
Publication of AR090582A1 publication Critical patent/AR090582A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones y métodos para elaborar y usar un vector de expresión que comprende un promotor y un inserto de ácido nucleico ligado operativamente al promotor, donde el inserto codifica uno o más ARN de horquilla corta (ARNhc) capaces de inhibir la expresión de un gen SRC-3 mediante interferencia de ARN, en donde dichos uno o más ARNhc comprenden una molécula de ARN bifuncional que activa un complejo de silenciamiento inducido por ARN dependiente del clivaje e independiente del clivaje para reducir el nivel de expresión de SRC-3 (coactivador del receptor nuclear 3), sistema de administración, método de administración, método para suprimir el crecimiento de un tumor.
ARP130101077A 2012-03-28 2013-04-03 METODOS Y COMPOSICIONES PARA TRATAR CANCER USANDO ARNhc SRC 3 BIFUNCIONAL AR090582A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261616873P 2012-03-28 2012-03-28

Publications (1)

Publication Number Publication Date
AR090582A1 true AR090582A1 (es) 2014-11-19

Family

ID=49235351

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101077A AR090582A1 (es) 2012-03-28 2013-04-03 METODOS Y COMPOSICIONES PARA TRATAR CANCER USANDO ARNhc SRC 3 BIFUNCIONAL

Country Status (4)

Country Link
US (1) US20130259925A1 (es)
AR (1) AR090582A1 (es)
TW (1) TW201346029A (es)
WO (1) WO2013148824A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106661576A (zh) * 2014-04-25 2017-05-10 斯特里克生物公司 用于癌症治疗的多靶向RNAi
AU2021372270A1 (en) 2020-10-28 2023-06-22 Baylor College Of Medicine Targeting of src-3 in immune cells as an immunomodulatory therapeutic for the treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002346049A1 (en) * 2001-07-05 2003-01-21 Georgetown University Medical Center Coactivators in the diagnosis and treatment of breast cancer
US20030224467A1 (en) * 2002-04-17 2003-12-04 Osborne C. Kent AIB1 as a prognostic marker and predictor of resistance to endocrine therapy
US8603991B2 (en) * 2005-11-18 2013-12-10 Gradalis, Inc. Individualized cancer therapy
US8252526B2 (en) * 2006-11-09 2012-08-28 Gradalis, Inc. ShRNA molecules and methods of use thereof
US8071752B2 (en) * 2007-01-29 2011-12-06 City Of Hope Multi-targeting short interfering RNAs
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
GB2468477A (en) * 2009-03-02 2010-09-15 Mina Therapeutics Ltd Double stranded RNA molecule comprising siRNA and miRNA precursors
CN102711788B (zh) * 2009-09-03 2014-12-24 格兰达利斯有限公司 使用组织特异性模拟肽配体的靶向递送
CA2777539C (en) * 2009-10-30 2016-09-13 Gradalis, Inc. Novel therapeutic rna interference technology targeted to the pdx-1 oncogene in pdx-1 expressing neuroendocrine tumors
US20110286979A1 (en) * 2010-05-20 2011-11-24 Gradalis, Inc. CHEMOSENSITIZATION BY BI-FUNCTIONAL SMALL HAIRPIN RNA (bi-shRNA)

Also Published As

Publication number Publication date
TW201346029A (zh) 2013-11-16
US20130259925A1 (en) 2013-10-03
WO2013148824A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
CY1123355T1 (el) Αντισωματα εναντι cd73 και χρησεις εξ αυτων
BR112018013930A2 (pt) vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus
ECSP14013223A (es) Métodos para tratar el cáncer por el uso de antagonistas de unión al eje pd-1 e inhibidores de mek
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
PH12020550833A1 (en) Rnai constructs for inhibiting pnpla3 expression
AR091004A1 (es) Arn en horquilla corta bifuncional (bi-arnhc) especifico de mutaciones de nucleotidos individuales en k-ras
PH12014502047A1 (en) Treatment of cancer with tor kinase inhibitors
CL2016003301A1 (es) Compuestos derivados del ácido amino-(piridin-4-carboxílico) sustituidos, inhibidores de la histona desmetilasa; composición farmacéutica, que los comprende, útiles en el tratamiento del cáncer, tales como el cáncer de próstata, mama, vejiga, pulmón y/o melanoma.
MX2018013216A (es) Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
DOP2014000199A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
BR112021025491A2 (pt) Métodos para uso de inibidores de rad51 para tratamento de câncer pancreático
PE20211225A1 (es) Constructos de arni para inhibir la expresion de pnpla3
CY1121859T1 (el) Μεθοδος παρασκευης αναστολεων συνθασης γλυκοζυλοκεραμιδης
MX2022001017A (es) Composiciones y metodos para inhibir la expresion del gen de sintasa de acido 5'-aminolevulinico 1 (alas1).
BR112017018861A2 (pt) métodos para tratar câncer mantendo perda hemizigótica de tp53
CL2019001002A1 (es) Métodos y composiciones para inmunoterapia por tusc2.
TR201910413T4 (tr) Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.
NZ740817A (en) Pcna inhibitors
EP4335502A3 (en) Modified u6 promoter system for tissue specific expression
MX2019011026A (es) Nueva vacuna de adn dirigida a pd-l1 para inmunoterapia de cancer.
AR090582A1 (es) METODOS Y COMPOSICIONES PARA TRATAR CANCER USANDO ARNhc SRC 3 BIFUNCIONAL
GB2507700A (en) Compositions and methods for treatment of metastatic cancer
TN2014000387A1 (en) Methods of treating cancer using aurora kinase inhibitors
AU2012342682A8 (en) Responsiveness to angiogenesis inhibitors
BR112016014882A2 (pt) Anticorpos monoclonais e processo para produção dos mesmos, composições, usos dos referidos anticorpos e composições, hibridoma murino i-4686, ácido nucleico isolado, vetor, e célula hospedeira

Legal Events

Date Code Title Description
FB Suspension of granting procedure